Literature DB >> 3334743

Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97.

S L Hu1, G D Plowman, P Sridhar, U S Stevenson, J P Brown, C D Estin.   

Abstract

p97 is a cell surface glycoprotein expressed at high levels in most human melanomas but present only in trace amounts in normal adult tissues. We are interested in exploring the possibility of using recombinant vaccinia virus to express a specific tumor-associated antigen as a vaccine against human cancer. To this end, we constructed a recombinant virus, v-p97NY, which contains the entire coding sequence for p97 under the control of the vaccinia virus 7.5K promoter. Upon infection of tissue culture cells, v-p97NY expressed high levels of a membrane-bound glycoprotein immunoreactive with a p97-specific monoclonal antibody. Immunization of mice with this recombinant elicited high-titered antibodies against p97. Spleen cells isolated from these mice proliferated in vitro when stimulated either with purified p97 protein or with syngeneic cells expressing p97 antigen. Delayed-type hypersensitivity was also observed in immunized mice after challenge with p97-expressing cells. These findings indicate the potential usefulness of v-p97NY and similar recombinants in tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3334743      PMCID: PMC250516     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

Review 1.  Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease.

Authors:  I J Fidler; G Poste
Journal:  Springer Semin Immunopathol       Date:  1982

2.  Biological and experimental consequences of the zonal composition of solid tumors.

Authors:  I J Fidler; I R Hart
Journal:  Cancer Res       Date:  1981-08       Impact factor: 12.701

3.  Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma-associated antigens.

Authors:  J C Bystryn
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

4.  A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate.

Authors:  W A Cassel; D R Murray; H S Phillips
Journal:  Cancer       Date:  1983-09-01       Impact factor: 6.860

5.  Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies.

Authors:  J P Brown; K Nishiyama; I Hellström; K E Hellström
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

6.  Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms.

Authors:  R G Woodbury; J P Brown; M Y Yeh; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

7.  Immunization to a syngeneic sarcoma by a monoclonal auto-anti-idiotypic antibody.

Authors:  J W Forstrom; K A Nelson; G T Nepom; I Hellström; K E Hellström
Journal:  Nature       Date:  1983 Jun 16-22       Impact factor: 49.962

8.  The isolation of simian virus 40 variants with specifically altered genomes.

Authors:  W W Brockman; D Nathans
Journal:  Proc Natl Acad Sci U S A       Date:  1974-03       Impact factor: 11.205

9.  Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity.

Authors:  G Urlaub; L A Chasin
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

10.  The effect of induced chronic viral infections on the immunologic diseases of New Zealand mice.

Authors:  G Tonietti; M B Oldstone; F J Dixon
Journal:  J Exp Med       Date:  1970-07-01       Impact factor: 14.307

View more
  8 in total

Review 1.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

2.  Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses.

Authors:  D Ronen; Y Teitz; N Goldfinger; V Rotter
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

Review 3.  Vaccinia virus vectors: new strategies for producing recombinant vaccines.

Authors:  D E Hruby
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

4.  Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters.

Authors:  Rakesh Kulkarni; Wen-Ching Chen; Ying Lee; Chi-Fei Kao; Shiu-Lok Hu; Hsiu-Hua Ma; Jia-Tsrong Jan; Chun-Che Liao; Jian-Jong Liang; Hui-Ying Ko; Cheng-Pu Sun; Yin-Shoiou Lin; Yu-Chiuan Wang; Sung-Chan Wei; Yi-Ling Lin; Che Ma; Yu-Chan Chao; Yu-Chi Chou; Wen Chang
Journal:  PLoS One       Date:  2021-09-09       Impact factor: 3.752

5.  Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus.

Authors:  S L Hu; J M Zarling; J Chinn; B M Travis; P A Moran; J Sias; L Kuller; W R Morton; G Heidecker; R E Benveniste
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

6.  Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.

Authors:  C D Estin; U S Stevenson; G D Plowman; S L Hu; P Sridhar; I Hellström; J P Brown; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

7.  Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1.

Authors:  P S Linsley; J A Ledbetter; E Kinney-Thomas; S L Hu
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

Review 8.  Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target.

Authors:  A P Zbar; N R Lemoine; M Wadhwa; H Thomas; D Snary; W A Kmiot
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.